MYR Pharmaceuticals is focused on developing and commercializing therapeutics for the treatment of chronic hepatitis B and D virus infections. Its lead compound, bulevirtide, is a first-in-class entry inhibitor that binds to the NTCP receptor for HDV and other indications, preventing reinfections and viral spread. Bulevirtide has received Orphan Drug Designations for the treatment of HDV infection from the European Medicines Agency (EMA) and from the U.S. Food & Drug Administration (FDA), as well as Breakthrough Therapy designation from the FDA and PRIority MEdicines (PRIME) scheme eligibility from the EMA. The British Medicines and Healthcare products Regulatory Agency (MHRA) has recently issued the Promising Innovative Medicine (PIM) designation for MYR’s lead compound Bulevirtide. In addition to hepatitis, bulevirtide has a potential for the treatment of a variety of inflammatory and metabolic diseases via additional pharmacological effects of NTCP inhibition. MYR Pharmaceuticals is headquartered in Bad Homburg, Germany, and was founded in 2011. The company has raised more than EUR 30 million from venture capital investors and private investors.